 Statistical analyses will be performed by a biostatistician. The primary intent of this study is to evaluate the ability of ethyl-EPA versus placebo to reduce TD symptoms in 12 weeks of treatment. The principal null hypothesis is therefore that ethyl-EPA will not differ from placebo on the primary efficacy measure. 